Qiu Xu
Qiu Xu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bai Minghua
Zhejiang Key Laboratory of Particle Radiotherapy Equipment , Hangzhou , Zhejiang , China
1 shared publication - Dai Qinghui
Zhejiang Key Laboratory of Particle Radiotherapy Equipment , Hangzhou , Zhejiang , China
1 shared publication - Fu Xinmo
Zhejiang Key Laboratory of Particle Radiotherapy Equipment , Hangzhou , Zhejiang , China
1 shared publication - Ji Zhu
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
1 shared publication - Rui Wang
Zhejiang Key Laboratory of Particle Radiotherapy Equipment , Hangzhou , Zhejiang , China
1 shared publication - Wang Lin
Zhejiang Key Laboratory of Particle Radiotherapy Equipment , Hangzhou , Zhejiang , China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 3905052
Integrative Multiomics and Single‐Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer
Background: Radiotherapy resistance limits colorectal cancer (CRC) treatment efficacy, with only 15%–20% of patients achieving a complete response. Validated biomarkers predicting treatment response and serving as therapeutic targets are critically needed. Methods: We performed integrative multiomics analysis of 200 CRC patients (GSE87211) with independent validation in 58 patients (GSE46862). Single‐cell RNA sequencing of 63,689 cells (GSE132465) determined cell‐type‐specific expression. Functional validation was conducted in radiotherapy‐resistant CRC cell lines through loss‐of‐function experiments including proliferation, migration/invasion, and radiosensitivity assays. Results: FKBP10 emerged as the only gene achieving statistical significance in both discovery (log2FC = 0.74, p = 0.0007) and validation (log2FC = 0.52, p = 0.032) cohorts among 48 radioresistance‐associated genes. Single‐cell profiling revealed that FKBP10 was predominantly expressed in cancer‐associated fibroblasts (CAFs, 51.5% of stromal cells), implicating CAF‐mediated stromal remodeling in resistance. FKBP10 knockdown significantly inhibited proliferation, colony formation (35%–40% reduction), migration (30%), and invasion (50%), while markedly enhancing radiosensitivity through increased DNA damage ( γ H2AX foci increased twofold, p < 0.01) and strand breaks (comet tail DNA: 22% → 43%, p < 0.01). Conclusions: This multiomics study establishes FKBP10 as a robust CAF‐derived biomarker and functional therapeutic target for radiotherapy resistance in CRC, providing a foundation for developing FKBP10‐targeted combination strategies for precision cancer treatment.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 3905052
Open AccessIntegrative Multiomics and Single‐Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer
Background: Radiotherapy resistance limits colorectal cancer (CRC) treatment efficacy, with only 15%–20% of patients achieving a complete response. Validated biomarkers predicting treatment response and serving as therapeutic targets are critically needed. Methods: We performed integrative multiomics analysis of 200 CRC patients (GSE87211) with independent validation in 58 patients (GSE46862). Single‐cell RNA sequencing of 63,689 cells (GSE132465) determined cell‐type‐specific expression. Functional validation was conducted in radiotherapy‐resistant CRC cell lines through loss‐of‐function experiments including proliferation, migration/invasion, and radiosensitivity assays. Results: FKBP10 emerged as the only gene achieving statistical significance in both discovery (log2FC = 0.74, p = 0.0007) and validation (log2FC = 0.52, p = 0.032) cohorts among 48 radioresistance‐associated genes. Single‐cell profiling revealed that FKBP10 was predominantly expressed in cancer‐associated fibroblasts (CAFs, 51.5% of stromal cells), implicating CAF‐mediated stromal remodeling in resistance. FKBP10 knockdown significantly inhibited proliferation, colony formation (35%–40% reduction), migration (30%), and invasion (50%), while markedly enhancing radiosensitivity through increased DNA damage ( γ H2AX foci increased twofold, p < 0.01) and strand breaks (comet tail DNA: 22% → 43%, p < 0.01). Conclusions: This multiomics study establishes FKBP10 as a robust CAF‐derived biomarker and functional therapeutic target for radiotherapy resistance in CRC, providing a foundation for developing FKBP10‐targeted combination strategies for precision cancer treatment.